Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers

Completed

• Conditions: Lymphoma

• Registration Number: NCT01639716
• Lead Sponsor: Nil Guler

Brief Summary

The investigators hypothesized that Non Hodgkin lymphoma is using T helper 2 pathways. So that the investigators decided to study of cytokines related to T helper 2 pathways. It is well known that parasites and allergic situations also use T helper 2 pathways. Because that the investigators excluded the patients have parasites and allergic situations. All the patients were over 18. The investigators included the patients with non Hodgkin lymphoma which new diagnosed. It is observational study. The investigators took blood before chemotherapy and four months later. The investigators did not interfere with which chemotherapy will be given to patients. This decision was belong to hematologist or oncologist who will treat the patient.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05
• Primary Completion: 2012-05
• Study Completion: 2012-06
• Status Verified: 2012-07
• Study First Submitted: 2012-07-04
• Study First Submitted QC: 2012-07-12
• Last Update Submitted: 2012-07-12
• Study First Posted: 2012-07-13
• Last Update Posted: 2012-07-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

• newly diagnosed non hodgkin lymphoma
• Diffuse large B cell lymphoma and T cell lymphoma patients

Exclusion Criteria

• under 18 age
• parasitosis
• allergic status

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interleukin 4 and Interleukin 10 levels as pg/mL in non hodgkin lymphoma	This study ended within 13 months	We will measure 31 patients and 27 healthy person's Interleukin 4 and Interleukin 10 levels as pg/mL at the beginning of the study. We determined all of the patients IPI score, LDH (U/L), crp (mg/L), erythrocyte sedimentation rate, hemoglobin (gr/dL), lymphocyte count in per µL, albumin (gr/dL) before the treatment. We wanted to check whether there is any correlation between well known prognostic markers (LDH, crp, albumin, stage, ECOG performance status) and Interleukin-4 and interleukin-10 levels.

Secondary Outcome Measures

Name	Time	Method
survey as months	During study which was 13 months	Our secondary goal was to determine the survey time as month from diagnoses to die from any reason or last evaluation during our study which was 13 months.

Trial Locations

Locations (1)

Ondokuz Mayis University Medical School; 🇹🇷 Samsun, Atakum, Turkey